NASDAQ$FULC
Fulcrum Therapeutics Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Announced second quarter 2022 financial results and provided a business update.
Fulcrum Therapeutics reported financial results for Q2 2022, highlighted by key milestones in their clinical programs including compelling proof of concept data for 6058 and the initiation of the first registrational trial for FSHD, while also announcing a strategic plan to realign internal resources to support clinical programs and extend cash runway.
- Presented initial data from Phase 1b trial in sickle cell disease (SCD), demonstrating rapid and robust increases in hemoglobin F (HbF).
- Announced enrollment of first patient in Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD).
- Announced strategic realignment to reduce operating expenses by $40-50M, prioritize clinical execution, and extend cash runway into mid-2024.
- Mel Hayes was promoted to the role of Chief Operating Officer and Curt Oltmans was promoted to the role of Chief Legal Officer.
Headline financials
Revenue & EPS history
Fulcrum Therapeutics · Revenue · Quarterly
$1.88M
Forward guidance
Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into mid-2024.
Tailwinds
- Completing enrollment in the Phase 1b SCD trial of FTX-6058.
- Initiating a registrational trial of FTX-6058 in SCD.
- Advancing the REACH trial.
- Submitting the next IND.
- Realignment of internal investments and operations to prioritize clinical programs.
Headwinds
- Delaying initiation of Phase 1b trial in non-SCD hemoglobinopathies, including beta-thalassemia.
- Strategic realignment will result in a workforce reduction of 25% of planned headcount.
- The company anticipates that subsequent events and developments will cause Fulcrum’s views to change.
- The company's views as of the date of the press release should not be relied upon as representing Fulcrum’s views as of any date subsequent to the date hereof.
- Fulcrum specifically disclaims any obligation to update forward-looking statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+5.2%
Avg return
Earnings day
+6.3%
Avg return
5 days after
+12.3%
Avg return
30 days after
62%
16 / 26 earnings
Positive
+142.5%
Q2 2021
Best reaction
-54.6%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -21.1% | -23.0% | -36.3% | |
| Q3 2025 | -6.6% | -9.8% | +9.4% | |
| Q1 2025 | +13.8% | +39.0% | +78.6% | |
| Q4 2024 | +0.0% | -3.0% | -16.5% | |
| Q3 2024 | -8.8% | -16.8% | +8.8% | |
| Q2 2024 | +7.1% | +0.6% | +1.7% | |
| Q1 2024 | +5.9% | +1.1% | +3.2% | |
| Q4 2023 | +6.1% | +12.9% | -3.0% | |
| Q3 2023 | +16.2% | -2.5% | +38.2% | |
| Q2 2023 | +3.4% | +5.5% | +49.7% | |
| Q1 2023 | +16.2% | -0.6% | -7.6% | |
| Q4 2022 | -28.0% | -36.6% | -62.0% | |
| Q3 2022 | +23.9% | +27.3% | +9.4% | |
| Q2 2022 | +8.4% | -6.2% | +7.1% | |
| Q1 2022 | -12.5% | -4.1% | -3.8% | |
| Q4 2021 | +17.4% | +37.8% | +113.9% | |
| Q3 2021 | -2.3% | -4.9% | -31.5% | |
| Q2 2021 | +142.5% | +175.3% | +233.9% | |
| Q1 2021 | +4.1% | +3.7% | -13.2% | |
| Q4 2020 | -17.7% | -17.4% | -17.8% | |
| Q3 2020 | +8.6% | +16.9% | +22.3% | |
| Q2 2020 | -54.6% | -55.5% | -54.7% | |
| Q1 2020 | +7.9% | +18.9% | +16.5% | |
| Q4 2019 | -2.2% | -27.8% | -49.4% | |
| Q3 2019 | +1.3% | +27.7% | +48.9% | |
| Q2 2019 | +7.2% | +6.1% | -25.5% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro